Resources
16 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 8/25/2023 (updated 3/26/2024)
The National Institute for Health Care Management (NIHCM) provided interactive graphic reports on the trends in overdose deaths using the latest data. The interactive infographic shows the effects combined drugs, such as fentanyl and xylazine, have on overdoses.
Posted 6/8/2022 (updated 3/27/2024)
This “Regional Emergency Disaster Response Preparedness Plan for Substance Use Disorder” workshop was designed to provide attendees with information on the importance of developing a plan to support populations with SUD/OUD during a disaster. Attendees heard how community members in rural and small urban communities are working together to ensure services and supports are available to populations with SUD during a disaster.
Posted 7/25/2022 (updated 3/27/2024)
The interactive graphics allow readers to explore how the crisis of overdose deaths involving opioid use has not only grown in magnitude since 2000, but has also changed in character.
Posted 8/23/2022 (updated 3/27/2024)
This observational study of 719 612 pharmacy claims data shows that OOP costs of naloxone grew substantially beginning in 2016. However, OOP costs did not increase for all patients and all brands of naloxone but primarily for uninsured patients and for the Evzio brand. The findings suggest that the OOP cost of naloxone has been an increasingly substantial barrier to naloxone access for uninsured patients, a population that constitutes nearly one-fifth of adults with opioid use disorder.
Posted 3/14/2023 (updated 3/27/2024)
Xylazine is a non-opioid that is approved for animals, and not FDA-approved for humans. New York State's Department of Health provides information on what it is, sources and trends, effects, why people use it, why clinicians should be concerned, and other information on Xylazine. Information about Xylazine is important to understand now that it has been showing up in illicit drug supply.
Posted 1/9/2023 (updated 3/27/2024)
The CDC report released in September 2022 highlights that more than 80% of pregnancy-related deaths were preventable. Among key findings, the report finds that one of the leading underlying causes of pregnancy-related death includes mental health conditions related to substance use disorder.
Posted 2/7/2023 (updated 3/27/2024)
The opioid epidemic is a result of a complex system of varied and interrelated factors. This webinar introduced a systems thinking approach and offers tools to address complex public health challenges. Additionally, the webinar described opportunities for grantees to further develop their capacity to apply systems thinking to a local opioid response.
Posted 12/1/2023 (updated 3/28/2024)
This publication highlights the Coordinated Opioid Recovery (CORE) Program in three Florida counties. The program integrates a new facet of Emergency Medical Services known as community paramedics. Since its launch in 2022 in Palm Beach County, Florida, CORE has expanded to include 12 additional Florida counties and takes a coordinated approach to recovery for individuals with SUD.
Posted 7/14/2023 (updated 3/28/2024)
The Centers for Disease Control and Prevention released data showing a significant increase – 276 percent in 21 jurisdictions from 2019 to 2022 – in overdose deaths involving Xylazine, a nonopioid sedative that’s been detected in illicitly manufactured fentanyl drug products.
Posted 7/26/2023 (updated 3/28/2024)
This session discussed the barriers typically encountered and workarounds such as money, staff, and location. We encouraged participants to bring successes, near successes, and non-successes in expanding access over the last 3 years.